Incidence and Burden of Lower-Risk Myelodysplastic Syndrome: A Nationwide Population Study
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2025.06.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Maud D'Aveni und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, University Hospital of Nancy, Université de Lorraine, Nancy, France. Electronic address: m.daveni-piney@chru-nancy.fr. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Micropalaeontological Society, Bristol-Myers Squibb Company.
Abstract (Originalsprache)
BACKGROUND: Myelodysplastic syndromes (MDS) are hematological malignancies that primarily affect older individuals, often leading to anemia, which significantly impacts quality of life. Until now, the management of lower-risk MDS (LR-MDS) typically includes erythropoiesis-stimulating agents (ESAs) as first-line treatment, with transfusions becoming necessary in cases of ESA resistance. This study aimed to assess the incidence, prevalence, and clinical outcomes of LR-MDS patients in France, using the French National Health Data System (SNDS). MATERIALS AND METHODS: A retrospective cohort of 822 LR-MDS patients treated between 2018 and 2022 was analyzed, with patients classified based on transfusion dependency. RESULTS: Results showed a median LR-MDS extrapolated incidence of 5,850 patients per year in France (between 6.9 to 9.3 cases per 100,000 persons). Transfusion-dependent (TD) patients represented 32.5% of the cohort. TD patients had a significantly lower 2-year overall survival rate of 53% compared to 70% in nontransfusion-dependent (NTD) patients. Over the study period, 41.9% (N = 112) died out of 267 newly treated LR-MDS patients. Also, there were 88 events of death (with no progression), 26 estimated progression to HR-MDS and 11 progression to acute myeloid leukemia. CONCLUSION: These findings highlight the substantial burden of transfusion dependency in LR-MDS patients, emphasizing the need for improved therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology Department, University Hospital of Nancy, Université de Lorraine, Nancy, France. Electronic address: m.daveni-piney@chru-nancy.fr.
- CH Côte Basque, DIM, Bayonne, France.
- Bristol Myers Squibb, HEOR, France.
- Heva, Epidemiology Department, Lyon, France.
- Bristol Myers Squibb, Medical, France.
- Service de Médecine Interne IUCT-Oncopole, CHU Toulouse, Université Paul Sabatier, Toulouse.
Förderung
- Micropalaeontological Society
- Bristol-Myers Squibb Company
Zitieren
APA
D'Aveni, M., Fernandes, J., Chartier, M., Cotté, F. E., Pagès, N., Panes, A., Schmidt, A., Webert, L., & Comont, T. (2025). Incidence and Burden of Lower-Risk Myelodysplastic Syndrome: A Nationwide Population Study. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.06.009
Vancouver
D'Aveni M, Fernandes J, Chartier M, Cotté FE, Pagès N, Panes A, et al. Incidence and Burden of Lower-Risk Myelodysplastic Syndrome: A Nationwide Population Study. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.06.009
BibTeX
@article{DAveni2025,
author = {D'Aveni, Maud and Fernandes, Jérôme and Chartier, Mélanie and Cotté, François-Emery and Pagès, Nicolas and Panes, Arnaud and Schmidt, Aurélie and Webert, Léa and Comont, Thibault},
title = {Incidence and Burden of Lower-Risk Myelodysplastic Syndrome: A Nationwide Population Study},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2025.06.009}
}
EUVIMED